Enormous Rivaroxaban Study Stopped Early For ‘ Overwhelming Efficacy ’

(Updated) –Oral anticoagulant reduced CV events in patients with coronary and peripheral disease. The very large COMPASS study has been stopped early for “overwhelming efficacy,” according to a press release issued by Bayer AG and Janssen, manufacturers of rivaroxaban (Xarelto). The phase 3 trial randomized 27,402 patients with coronary artery disease (CAD) and peripheral artery...Click here to continue reading...

Source: CardioBrief - February 8, 2017 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Anticoagulant CAD NOAC PAD rivaroxaban Source Type: blogs